Literature DB >> 10522879

Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy.

J M Shefner1, A G Reaume, D G Flood, R W Scott, N W Kowall, R J Ferrante, D F Siwek, M Upton-Rice, R H Brown.   

Abstract

OBJECTIVE: To characterize the motor neuron dysfunction in two models by performing physiologic and morphometric studies.
BACKGROUND: Mutations in the gene encoding cytosolic superoxide dismutase 1 (SOD1) account for 25% of familial ALS (FALS). Transgenes with these mutations produce a pattern of lower motor neuron degeneration similar to that seen in patients with FALS. In contrast, mice lacking SOD1 develop subtle motor symptoms by approximately 6 months of age.
METHODS: Physiologic measurements, including motor conduction and motor unit estimation, were analyzed in normal mice, mice bearing the human transgene for FALS (mFALS mice), and knockout mice deficient in SOD1 (SOD1-KO). In addition, morphometric analysis was performed on the spinal cords of SOD1-KO and normal mice.
RESULTS: In mFALS mice, the motor unit number in the distal hind limb declined before behavioral abnormalities appeared, and motor unit size increased. Compound motor action potential amplitude and distal motor latency remained normal until later in the disease. In SOD1-KO mice, motor unit numbers were reduced early but declined slowly with age. In contrast with the mFALS mice, SOD1-KO mice demonstrated only a modest increase in motor unit size. Morphometric analysis of the spinal cords from normal and SOD1-KO mice showed no significant differences in the number and size of motor neurons.
CONCLUSIONS: The physiologic abnormalities in mFALS mice resemble those in human ALS. SOD1-deficient mice exhibit a qualitatively different pattern of motor unit remodeling that suggests that axonal sprouting and reinnervation of denervated muscle fibers are functionally impaired in the absence of SOD1.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10522879     DOI: 10.1212/wnl.53.6.1239

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  45 in total

1.  Molecular and biochemical characterization of a unique mutation in CCS, the human copper chaperone to superoxide dismutase.

Authors:  Peter Huppke; Cornelia Brendel; Georg Christoph Korenke; Iris Marquardt; Anthony Donsante; Ling Yi; Julia D Hicks; Peter J Steinbach; Callum Wilson; Orly Elpeleg; Lisbeth Birk Møller; John Christodoulou; Stephen G Kaler; Jutta Gärtner
Journal:  Hum Mutat       Date:  2012-05-16       Impact factor: 4.878

2.  SOD1 targeted to the mitochondrial intermembrane space prevents motor neuropathy in the Sod1 knockout mouse.

Authors:  Lindsey R Fischer; Anissa Igoudjil; Jordi Magrané; Yingjie Li; Jason M Hansen; Giovanni Manfredi; Jonathan D Glass
Journal:  Brain       Date:  2010-11-14       Impact factor: 13.501

3.  Calcium dysregulation mediates mitochondrial and neurite outgrowth abnormalities in SOD2 deficient embryonic cerebral cortical neurons.

Authors:  Qijin Zhao; Daoyuan Lu; Jing Wang; Beibei Liu; Heping Cheng; Mark P Mattson; Aiwu Cheng
Journal:  Cell Death Differ       Date:  2018-11-02       Impact factor: 15.828

Review 4.  Genetically engineered models relevant to neurodegenerative disorders: their value for understanding disease mechanisms and designing/testing experimental therapeutics.

Authors:  P C Wong; H Cai; D R Borchelt; D L Price
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 5.  Recent advances in RNA interference therapeutics for CNS diseases.

Authors:  Pavitra S Ramachandran; Megan S Keiser; Beverly L Davidson
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

6.  The nature and mechanism of superoxide production by the electron transport chain: Its relevance to aging.

Authors:  F Muller
Journal:  J Am Aging Assoc       Date:  2000-10

7.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study.

Authors:  Timothy M Miller; Alan Pestronk; William David; Jeffrey Rothstein; Ericka Simpson; Stanley H Appel; Patricia L Andres; Katy Mahoney; Peggy Allred; Katie Alexander; Lyle W Ostrow; David Schoenfeld; Eric A Macklin; Daniel A Norris; Georgios Manousakis; Matthew Crisp; Richard Smith; C Frank Bennett; Kathie M Bishop; Merit E Cudkowicz
Journal:  Lancet Neurol       Date:  2013-03-29       Impact factor: 44.182

8.  Defective neuromuscular transmission in the SOD1 G93A transgenic mouse improves after administration of human umbilical cord blood cells.

Authors:  Nizar Souayah; K M Coakley; R Chen; Norman Ende; Joseph J McArdle
Journal:  Stem Cell Rev Rep       Date:  2012-03       Impact factor: 5.739

Review 9.  From animal models to human disease: a genetic approach for personalized medicine in ALS.

Authors:  Vincent Picher-Martel; Paul N Valdmanis; Peter V Gould; Jean-Pierre Julien; Nicolas Dupré
Journal:  Acta Neuropathol Commun       Date:  2016-07-11       Impact factor: 7.801

10.  Motor unit number estimate as a predictor of motor dysfunction in an animal model of type 1 diabetes.

Authors:  Nizar Souayah; Joseph G Potian; Carmen C Garcia; Natalia Krivitskaya; Christine Boone; Vanessa H Routh; Joseph J McArdle
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-07-14       Impact factor: 4.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.